Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Sleep-disordered breathing (SDB) is a known risk factor for hypertension. Despite the well-established link between HIV infection and hypertension, it remains to be determined whether HIV infection modifies the association between SDB and hypertension.

Setting: The Multicenter AIDS Cohort Study.

Methods: SDB was assessed using in-home polysomnography in 779 men (436 with and 343 without HIV). The apnea-hypopnea index (AHI) based on oxyhemoglobin desaturation threshold of ≥3% or arousal (AHI 3a ) and ≥4% (AHI 4 ) along with oxygen desaturation index (ODI) were used to quantify SDB severity. Hypertension was defined as a blood pressure ≥140/90 mm Hg, use of antihypertensive medication, or self-report of a clinical diagnosis. The associations between HIV, SDB, and hypertension were characterized using multivariable logistic regression.

Results: The prevalence of hypertension and SDB (AHI 3a ≥ 5 events/hr) was high, with estimates of 53.8% and 82.8%, respectively. Among men without SDB, HIV was independently associated with hypertension, with an adjusted odds ratio (OR) of 3.05 [95% confidence interval (CI): 1.33 to 7.01]. In men without HIV, SDB was associated with hypertension (OR: 2.93; 95% CI: 1.46 to 5.86). No significant increase in the odds of hypertension was noted in men with both HIV and SDB compared with men with either factor alone, with an OR of 3.24 (95% CI: 1.62 to 6.47). These results were consistent across different measures used to define SDB (AHI 3a , AHI 4 , ODI 3 , and ODI 4 ).

Conclusions: Predictors of hypertension differed by HIV status. SDB was associated with hypertension in men without HIV, but not in men with HIV. Among men with HIV, SDB did not affect the odds of hypertension.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10824508PMC
http://dx.doi.org/10.1097/QAI.0000000000003276DOI Listing

Publication Analysis

Top Keywords

men hiv
24
hiv sdb
16
hypertension
12
hypertension men
12
hiv
12
sdb
12
associated hypertension
12
men
9
sleep-disordered breathing
8
hiv infection
8

Similar Publications

Background: Oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) preexposure prophylaxis (PrEP) effectiveness against HIV acquisition highly depends on adherence. For men who have sex with men, a dosing study in the United States (US) population defined clinically meaningful tenofovir diphosphate (TFV-DP) thresholds in dried blood spots (DBS) based on the rounded 25th percentile for 2, 4, and 7 doses/week as 350, 700, and 1,250 fmol/punch. However, divergent efficacy results in the first generation randomized clinical trials of F/TDF PrEP among African women led to several hypotheses to question whether the pharmacology and adherence requirement for oral F/TDF PrEP may be different in cisgender women compared to what is already established for men.

View Article and Find Full Text PDF

Background: Men who have sex with men (MSM) and transgender women (TGW) are at elevated mpox risk; vaccination can greatly reduce that risk. We assessed mpox awareness and vaccine acceptability among MSM and TGW.

Methods: In 2022, hybrid-mode (offline/online) surveys were administered among 250 MSM and 251 TGW in Chennai, India.

View Article and Find Full Text PDF

Persistent high-risk human papillomavirus (hHPV) infection, especially HPV-16, plays a central role in the development of high-grade squamous intraepithelial lesions (HSIL). This study aimed to evaluate the performance of co-testing (cytology and hHPV detection) in a real-world cohort of men who have sex with men (MSM) and transgender women (TW) living with HIV. We conducted a prospective study (2017-2023) at a tertiary care center in Spain.

View Article and Find Full Text PDF

Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.

View Article and Find Full Text PDF

Background: The global spread of antimicrobial resistance (AMR) in threatens empiric single-dose gonorrhoea treatment. Enhanced global AMR surveillance is imperative. We report i) gonococcal antimicrobial susceptibility and resistance data from 2023 in the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (WHO EGASP) in the WHO Western Pacific Region (Cambodia, the Philippines, Viet Nam), Southeast Asian Region (Indonesia, Thailand), and African Region (Malawi, South Africa, Uganda, Zimbabwe), and ii) metadata of the gonorrhoea patients.

View Article and Find Full Text PDF